Corporate Overview/History

Corporate Overview

Company Name Solasia Pharma K.K.
Address 4F SUMITOMO FUDOSAN SHIBA-KOEN TOWER,
2-11-1 Shiba-koen, Minato-ku, Tokyo 105-0011 Japan
Phone Number +81 3 5843 8045
Date of Establishment December 2006
President & CEO Yoshihiro Arai
Scope of Business Development, marketing, import/export of pharmaceutical products and medical devices, etc.
Access Direction By Train
JR “Hamamatsucho Station” Kanasugibashi Exit, 7 minutes walk
Toei Subway Mita Line “Shiba-koen Station” A3 Exit, 2 minutes walk

Subsidiary Company (Wholly Owned)

Company Name 苏爱康医药信息咨询(上海)有限公司
Solasia Medical Information Consulting (Shanghai) Co. Ltd.
Website
[ Main Office/Shanghai Office ]
Address 上海市浦东新区世纪大道1196号世纪汇办公楼二座25层07单元
Unit07, 25F, II, Century Link Tower, No. 1196 Century Avenue, PuDong New District, Shanghai, China 200120
Phone Number +86-21-5028-1230
[ Beijing Office ]
Address 北京市朝阳区朝阳门外大街甲六号万通中心D座3层
3Floor, Tower D, Vantone Center, No.6 Chaoyangmenwai Street, Chaoyang District ,Beijing, China 100022
Phone Number +86-10-5907-0428
[ Guangzhou Office ]
Address 广州越秀区中山三路33号中华国际中心A塔14层
14/F, Tower A, China International Centre, No. 33 Zhongshan San Road, Yuexiu District, Guangzhou, China 510055
Phone Number +86-20-8114-8420

History/Timeline

Apr 2022 Solasia listed it’s shares on Tokyo Stock Exchange, Growth
Oct 2021 License Agreement with Nippon Kayaku Co., Ltd. for commercialization of darinaparsin (SP-02) in Japan
Sep 2020 Launched episil® (SP-03) in South Korea
Aug 2020 License Agreement with Isofol Medical AB for exclusive license of arfolitixorin (SP-05) in Japan
Jan 2020 License Agreement with Synex for commercialization of episil® (SP-03) in South Korea
Dec 2019 License Agreement with Maruho Co., Ltd. for commercialization of PledOx® (SP-04) in Japan
Oct 2019 Obtained Commercial Approval of episil® (SP-03) in South Korea
Jul 2019 Launched episil® (SP-03) in China
Mar 2019 Launched Sancuso® (SP-01) in China
Feb 2019 Obtained Approval of episil® (SP-03) in China as new medical device
Dec 2018 Open Guangzhou Office in China
Aug 2018 License and Distribution Agreement with HB Human BioScience SAS for exclusive license of darinaparsin (SP-02) in Latin America (Colombia, Peru, Ecuador, Venezuela, Chile, Panama, Costa Rica, and Guatemala)
Aug 2018 License and Distribution Agreement with Camurus AB for exclusive license of episil® (SP-03) in South Korea
Jul 2018 Obtained Approval of Sancuso® (SP-01) in China
Nov 2017 License Agreement with PledPharma AB (currently Egetis Therapeutics AB) for exclusive license of PledOx® (SP-04) in Japan, China and other Asian territories
Jul 2017 Obtained Approval of episil® (SP-03) in Japan as new medical device
Mar 2017 Solasia listed it’s shares on Tokyo Stock Exchange, Mothers
Feb 2017 License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of episil® (SP-03) in China excluding Beijing, Shanghai, Guangzhou and Taiwan
Nov 2016 License and Collaboration Agreement with Meiji Seika Pharma for episil® (SP-03) in Japan
Nov 2015 License Agreement with Lee’s Pharmaceutical (HK) Limited for the commercialization of Sancuso® (SP-01) in China excluding Beijing, Shanghai, Guangzhou, Hong Kong, Macau and Taiwan
Mar 2015 Licensed and Distribution Agreement with Camurus AB for exclusive license of episil® (SP-03) in Japan and China
Dec 2014 Establishment of the subsidiary in Shanghai
Jul 2014 License Agreement with ZIOPHARM Oncology Inc. (currently Alaunos Therapeutics) for global license and collaboration for darinaparsin (SP-02)
Jan 2013 Open Shanghai Office in China
Dec 2011 Open Beijing Representative Office in China
Mar 2011 License Agreement with ZIOPHARM Oncology Inc. (currently Alaunos Therapeutics) for exclusive rights to darinaparsin (SP-02) in Japan, China, and other Asian territories
Feb 2010 License Agreement with Kyowa Hakko Kirin Co., Ltd. (currently Kyowa Kirin) for the sublicense of Sancuso® (SP-01) in Taiwan, Hong Kong, Singapore & Malaysia
Sep 2008 Company name changed to Solasia Pharma K.K.
May 2008 License Agreement with ProStrakan (currently Kyowa Kirin Services Limited) for exclusive rights to Sancuso® (SP-01) in Japan, China, and other Asian territories
Dec 2006 Business started as JapanBridge in the United States with investments by MPM Capital, US and ITOCHU Corporation, JP
PAGE TOP